Corrigendum to “Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.” Kidney Int. 2020;97:1287–1296 (Kidney International (2020) 97(6) (1287–1296), (S0085253820301526), (10.1016/j.kint.2020.01.035))
Version 2 2024-06-06, 17:08
Version 1 2023-02-23, 00:59
journal contribution
posted on 2024-06-06, 17:08 authored by E Rondeau, M Scully, G Ariceta, T Barbour, S Cataland, N Heyne, Y Miyakawa, S Ortiz, E Swenson, M Vallee, SS Yoon, D Kavanagh, H Haller, S Babu, N Broeders, N Lietar, F Brown, P Campbell, JM Campistol, M Blasco, P Chowdhury, T Kasimatis, L Cirami, L Caroti, G Antognoli, Y Delmas, V Dobronravov, A Gaeckler, C Garrouste, G Greenwood, S Griffin, CC Huang, IR Chen, S Huang, JS Kim, G La Manna, G Comai, M Cappuccilli, M Le Quintrec, G Jeantet, I Fumie, Y Luque, J Menne, J Morelle, E Goffin, A Muhlfeld, S Nagaraj, G Arepally, D Oh, M Okumi, MP Terente, E Gutierréz, P Rodriguez, F Provot, U Schönermarck, M Fischereder, NR Terrada, B Seitz-Polski, G Favre, S Boyer-Suavet, M Vinogradova, T Kirsanova, EKS WongCorrigendum to “Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.” Kidney Int. 2020;97:1287–1296 (Kidney International (2020) 97(6) (1287–1296), (S0085253820301526), (10.1016/j.kint.2020.01.035))
